NASDAQ · OFIX

Orthofix Medical Inc.. (DE)

$12.37 +$1.12 (+9.96%) 1D Market open

Key Metrics

$454.74M
Market cap
P/E · TTM
$825.37M
Revenue · TTM
−$60.01M
Net income
EPS · TTM $-1.53
Dividend yield
Free cash flow −$4.42M
Beta · 1Y 0.71
EBITDA · TTM −$3.13M
Gross margin 70.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 6
    The stock moved +16.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 6
  • Jun 22
    From its Feb 20 high, the share price fell 35%.

    Peak close $13.87 on Feb 20; trough close $8.95 on Jun 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • May 21
    The stock moved -14.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 21

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$454.74M
Enterprise value$555.80M
Shares outstanding40.4M
52-wk range$8.85 – $16.99
Avg volume · 20D274.5K
Net cash −$101.06M
Book value / share$11.11
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Orthofix Medical Inc.. (DE)
IPO dateApr 24, 1992
Employees1605

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.55
P/FCF
EV/EBITDA
EV/Sales0.67
Graham №

Profitability

Gross 70.7%
Operating -7.2%
Net -7.3%
FCF -0.5%
ROE / ROIC -12.8% · -11.2%

Financial Health

Current ratio2.87
Quick ratio1.76
Debt / equity0.51
Debt / EBITDA -70.76
Net cash −$101.06M
Working capital$300.49M

Cash Flow · TTM

Operating CF $34.13M
Capex −$38.55M
Free cash flow −$4.42M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

1.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings